Clinical Trials Logo

Clinical Trial Summary

One of the greatest problems in renal transplantation is the shortage of donor kidneys. Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion injury. The increased ischemia-reperfusion injury results in an increased immune activation, which can lead to more injury of the kidney and additional acute rejections. The hypothesis of this trial is that ischemia-reperfusion injury can be diminished by ATG. ATG could have additional favourable effects. To investigate this half of the patients is treated with additional ATG to the standard immunosuppressive treatment. Calcineurin inhibitors are not diminished during the first days after transplantation to investigate whether ATG has special effects on ischemia-reperfusion injury.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00733733
Study type Interventional
Source Radboud University
Contact Andries Hoitsma, Prof. Dr.
Phone +31243614761
Email a.hoitsma@nier.umcn.nl
Status Recruiting
Phase Phase 3
Start date January 2008
Completion date June 2010

See also
  Status Clinical Trial Phase
Completed NCT00913796 - Metabolic Acidosis in Renal Transplant Patients Phase 2
Completed NCT03270462 - CNS Study of Patients Switching From Tacrolimus to Envarsus Phase 4